[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354691-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354691-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-cell-selective-ectopic-expression-of-cd20-as-an-antigen-enables-rituximab-repurposing-for-solid-tumour-immunotherapy-research-article","Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy - research article","","Despite the clinical success of cancer immunotherapies, antigen-related problems—downregulation, loss, and off-tumour toxicity—often limit efficacy. A strategy is described that artificially and specifically expresses a clinically validated antigen on variant tumours, repurposing approved antibody drugs for cancers outside their indications. Tumours received CD20 gene delivery via adeno-associated virus under an NF-κB-specific promoter, followed by rituximab treatment. Selective CD20 expression activated NK-cell ADCC and macrophage ADCP, showing efficacy across multiple in vitro, 3D, organoid, and in vivo models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-cell-selective-ectopic-expression-of-cd20-as-an-antigen-enables-rituximab-repurposing-for-solid-tumour-immunotherapy-research-article/354691/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-cell-selective-ectopic-expression-of-cd20-as-an-antigen-enables-rituximab-repurposing-for-solid-tumour-immunotherapy-research-article/354691.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in solid tumour immunotherapy?","Question",{"text":63,"@type":64},"The study addresses limited effectiveness caused by antigen-related issues such as downregulation, loss, and off-tumour toxicity in solid tumours.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is CD20 expression targeted to tumours in this strategy?",{"text":68,"@type":64},"A CD20 gene is delivered to tumours using adeno-associated virus, controlled by an NF-κB-specific promoter to drive tumour-selective ectopic expression.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune mechanisms are activated after rituximab treatment?",{"text":72,"@type":64},"Rituximab engages multiple antibody-dependent effector mechanisms, including NK-cell-mediated ADCC and macrophage-mediated ADCP, contributing to antitumour activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354691,1790673651,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10.1002/ctm2.70804  \nRESEARCH ARTICLE  \nCancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy  \nZiyan Kong1  Yile Wang1  Yunqi Zhao1  Lu Wang2   Zhimin Fan2   Yongqian Shu3  Jinke Wang1   \n1 School of Biological Science and Medical Engineering, Southeast University, Nanjing, China  \n2Jiangsu Clinical Innovation Center for Anorectal Diseases ofT.C.M, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China  \n3 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China  \nCorrespondence  \nJinke Wang, Sipailou 2, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.  \n[Email:](Email: wangjinke@seu.edu.cn)[ wangjinke@seu.edu.cn](Email: wangjinke@seu.edu.cn)  \nGraphical Abstract  \n∙ A recombinant AAV delivered tumour gene therapy.  \n∙ NF-κB drives tumour-selective antigen (e.g., CD20) expression.  \n∙ Ectopic CD20 enables rituximab repurposing to solid tumours.  \n∙ ADCC, ADCP, and CDC contribute to the antitumour activity.  \nClin. Transl. Med. 2026;16:e70804 .  \n[https://doi.org/10.1002/ctm2.70804](https://doi.org/10.1002/ctm2.70804)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70804  \nRESEARCH ARTICLE  \nCancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy  \nZiyan Kong1  Yile Wang1  Yunqi Zhao1  Lu Wang2   Zhimin Fan2   Yongqian Shu3  Jinke Wang1   \n1 School of Biological Science and Medical Engineering, Southeast University, Nanjing, China  \n2Jiangsu Clinical Innovation Center for Anorectal Diseases ofT.C.M, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China  \n3 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China  \nCorrespondence  \nJinke Wang, Sipailou 2, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. [Email:](Email: wangjinke@seu.edu.cn)[ wangjinke@seu.edu.cn](Email: wangjinke@seu.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Number: 62371126  \nAbstract  \nBackground: Despite the clinical success of cancer immunotherapies, their efficacy is often compromised by antigen-related problems, including downregulation, loss, and off-tumour toxicity.  \nMethods: To overcome these limitations that challenge the current immunotherapies dependent on native antigens, we here describe a new cancer immunotherapy strategy that artificially and specifically expresses a clinically validated antigen on variant tumours and thus repurposes clinical antibody drugs to treat cancers not belonging to their indications. To authenticate the strategy, we delivered a CD20 gene under the control of an NF-κB-specific promoter to tumours by adeno-associated virus and then treated them with a CD20 antibody, rituximab.  \nResults: We found that CD20 was selectively expressed in tumours, and subsequent rituximab treatment engaged multiple antibody-dependent effector mechanisms, including NK-cell-mediated ADCC and macrophage-mediated ADCP. We demonstrated that this strategy is effective not only in variantcultivated cancer cells, HCT116 spheroids, and patient-derived organoids of human colorectal cancer, but also in a humanized mouse with an HCT116 xenograft and immunocompetent mouse with an MC38 transplant. The strategy showed high cancer cell specificity in both in vitro and in vivo models, resulting in high therapeutic efficacy.  \nConclusion: This strategy thus creates a new modality of cancer immuneredirection therapy by repurposing both the clinically validated antigen and antibody.  \nKEYWORDS  \nantibody, antigen, cancer, immunotherapy, repurpose  \nThis is an open access article under the terms of the Creative Commons Attribution License, whi","cbCaipXir5lSNTuV","https://ap.wps.com/l/cbCaipXir5lSNTuV","pdf",4135605,25,"English","# Abstract\n## Methods\n## Results\n## Conclusion\n# Background\n## Antigen limitations in immunotherapy\n## Artificial antigen strategies","[{\"question\":\"What problem does the study address in solid tumour immunotherapy?\",\"answer\":\"The study addresses limited effectiveness caused by antigen-related issues such as downregulation, loss, and off-tumour toxicity in solid tumours.\"},{\"question\":\"How is CD20 expression targeted to tumours in this strategy?\",\"answer\":\"A CD20 gene is delivered to tumours using adeno-associated virus, controlled by an NF-κB-specific promoter to drive tumour-selective ectopic expression.\"},{\"question\":\"What immune mechanisms are activated after rituximab treatment?\",\"answer\":\"Rituximab engages multiple antibody-dependent effector mechanisms, including NK-cell-mediated ADCC and macrophage-mediated ADCP, contributing to antitumour activity.\"}]","Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy - research article | PDF",1790113070,63,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fdde70fed2cd57b16186b58d4c038ee.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c256492eced1532872ff69fe9cef7b8.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26a9fdbca748ef3693dcb14c25c0d605.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/881d61a10774a7ca4c84a7d2093df870.webp",980,1287]